GM29496
iPSC from Fibroblast
Description:
BEHCET SYNDROME
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases PIGI Consented Sample |
Protocols |
Protocol PDF |
Cell Type
|
Stem cell
|
Cell Subtype
|
Induced pluripotent stem cell
|
Transformant
|
Reprogrammed (Sendai)
|
Sample Source
|
iPSC from Fibroblast
|
Race
|
White
|
Ethnicity
|
Not Hispanic/Latino
|
Ethnicity
|
Hungarian, Belgian, German, French, English
|
Country of Origin
|
USA
|
Family History
|
Y
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
ISCN
|
46,XX[20]
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
13 |
|
Induced Pluripotent Stem Cell |
The parental cell line was recovered reprogrammed to an induced pluripotent stem cell line and expanded. The expanded line was evaluated for viability surface antigen expression and alkaline phosphatase activity. Pluripotency was assessed via embryoid body (EB) formation. Steady-state mRNA expression patterns of undifferentiated iPSC and EBs were determined via real-time PCR. Characterization data are included in the Certificate of Analysis. |
|
Remarks |
Clinically affected; Symptoms include: uveitis, ulcers, joint pain and inflammation, vulvar ulcers, kidney failure, ulcerative colitis, and blindness; Assistive devices include: wheelchair, use of guide dog, and oxygen; Medications include: Metoprolol, Diazepam, and Fentanyl Transdermal Patch; Has undergone laser eye surgery, and have had cataract surgery twice; Son is also clinically affected (not listed in catalog). Researchers purchasing hiPSCs from the NIGMS Repository are responsible for any limited use label licenses (LULLs) applicable to the cell line purchased. The applicable LULL to this line is Sendai-CytoTune. |
Passage Frozen |
13 |
Split Ratio |
1:10 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
mTeSR1 |
Serum |
none Not inactivated |
Substrate |
Matrigel |
Supplement |
- |
|
|